All the news Showing 10 of 56 articles from: Treatment outcomesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Curing hepatitis C reduces deaths and liver disease Keith Alcorn / 17 April 2018 Curing hepatitis C infection significantly reduces deaths from liver disease and reduces the incidence of decompensation, two large prospective studies from Italy and Scotland show. The findings were presented on ... Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... Hepatitis C cure leads to improved quality of life Liz Highleyman / 23 October 2017 People who were cured of hepatitis C with direct-acting antivirals (DAAs) had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study ... Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment Michael Carter / 10 August 2017 For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study – ... HCV therapy with SVR reduces the risk of several non-liver-related diseases commonly seen in people with chronic HCV Michael Carter / 06 July 2017 The risk of several non-liver complications associated with chronic hepatitis C virus (HCV) infection is reduced after interferon-based treatment that achieves a sustained virological response (SVR), investigators from the United ... Experts question Cochrane review of hepatitis C treatment Keith Alcorn / 15 June 2017 A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticised by doctors and advocates for its conclusion that there is no ... Children with hepatitis C respond well to sofosbuvir/ledipasvir Liz Highleyman / 22 April 2017 Almost all children with hepatitis C, aged 6 to 11 years, who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver ... Curing hepatitis C reduces cardiovascular risk Keith Alcorn / 20 April 2017 Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... Curing hepatitis C reduces the risk of diabetes & kidney failure in people with HIV/HCV co-infection Keith Alcorn / 01 February 2017 Curing hepatitis C infection substantially reduces the risk of developing type 2 diabetes in people with HIV/hepatitis C virus (HCV) co-infection, but does not reduce the risk of cardiovascular disease, ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive